Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961342 | 0.94 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL15364641 | 0.94 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL3957961 | 0.94 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL15019147 | 0.92 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL15019149 | 0.92 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL303066 | 0.89 | GSTP1 (0.36) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL2671273 | 0.89 | GSTP1 (0.36) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL12384955 | 0.85 | ATM (0.48) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL14993637 | 0.84 | LMNA (0.39) | HCAR2ATMLMNAHTT | |
| SCHEMBL106615 | 0.82 | TSHR (0.47) | ALDH1A1THRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336151-A1 | Silicon-Containing Fumaric Acid Esters | BIOGEN MA INC. | 2014-11-13 | — | — | US | claimed |
| EP-2791181-A1 | SILICON-CONTAINING FUMARIC ACID ESTERS | Biogen Idec MA Inc. (US) | 2014-10-22 | — | — | EP | claimed |
| WO-2013090799-A1 | SILICON-CONTAINING FUMARIC ACID ESTERS | BIOGEN IDEC MA INC. (US) | 2013-06-20 | — | — | WO | claimed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-115531366-A | Method of treating multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115501218-A | Methods of treating multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114146081-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114146080-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114146079-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| EP-2811994-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | Biogen Idec MA Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014190056-A2 | PRODRUGS AND DRUGS | BIOGEN IDEC MA INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20140336151-A1 | Silicon-Containing Fumaric Acid Esters | BIOGEN MA INC. | 2014-11-13 | — | — | US | disclosed |
| EP-2791181-A1 | SILICON-CONTAINING FUMARIC ACID ESTERS | Biogen Idec MA Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN IDEC MA INC. | 2013-08-22 | — | — | US | disclosed |
| WO-2013119677-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN IDEC MA INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013090799-A1 | SILICON-CONTAINING FUMARIC ACID ESTERS | BIOGEN IDEC MA INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2009147024-A1 | BINDERS BASED ON POLYMERS CONTAINING ALPHA-SILANE GROUPS | WACKER CHEMIE AG (DE) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009033908-A2 | MOISTURE CROSS-LINKABLE POLYMERS BASED ON ALPHA-HETEROATOM SUBSTITUTED SILANES | WACKER CHEMIE AG (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | HCAR2 1752/4885KEAP1 557/4885NFE2L2 440/4885 |
| US-20140336151-A1 | Silicon-Containing Fumaric Acid Esters | FAH, SCLY, FH | HCAR2 704/4885KEAP1 819/4885NFE2L2 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.